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Loss of ovarian hormones (ie. menopause) results in a significant increase in risk 
for developing the metabolic syndrome.  Thus, the purpose of this study is to investigate 
the effectiveness of exercise in preventing the metabolic syndrome in a model of 
menopause.  Female C57/BL6 mice were divided into three groups, ovariectomized 
(OVX), SHAM, and ovariectomized supplemented with 17β-estradiol (OVX+E2), with 
mice placed in either voluntary running wheel cages or standard cages for eight weeks.  
OVX animals ran significantly less than SHAM animals, with the OVX+E2 group 
exhibiting a partial recovery in distance.  Visceral fat mass and blood glucose levels were 
elevated in the OVX sedentary group as compared to SHAM and OVX+E  groups. 2  
Voluntary wheel running and 17-β estradiol supplementation attenuated increases in 
visceral fat mass, blood glucose levels, and ERK1/2 phosphorylation in OVX animals, 
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 Over the past twenty years, the incidence of obesity among adults and children 
alike has risen dramatically (138).  While most of the upward trend in obesity is 
attributed to decreased physical activity (201), other physiological factors have been 
linked to weight gain.  For example, various metabolic disorders, such as menopause and 
hypothyroidism (214) have been associated with changes in body fat, body composition, 
and total body weight (50; 149; 175; 184).  Menopause begins approximately in the fifth 
decade of life and currently it is estimated that 1 in 3 women are postmenopausal (36).  
Post-menopausal females are at greater risk of developing obesity than pre-menopausal 
women.  Thus, a large percentage of the female population is at increased risk for 
developing obesity based on ovarian hormone status.    
In studying the physiological changes associated with menopause, it is important 
to understand the function of estrogens.  Estrogens are steroid hormones which operate as 
the primary sex hormones in females.  Three major types exist: estradiol, estriol, and 
estrone, with 17β-estradiol the predominant form present in pre-menopausal females (21).  
Estrogens play an important role in the development of female secondary sex 
characteristics, regulation of the menstrual cycle, and bone growth (129).  During 
menopause, production of estrogens by the ovary declines and almost stops completely 
(49; 185; 206).  Not only does this drop in production of estrogens result in the loss of 
menses, but it has also been associated with changes in metabolism, fat distribution, 
blood lipid profile, and blood glucose levels (129; 184).  Thus, conditions such as the 
metabolic syndrome, cardiovascular disease, and osteoporosis may result as the level of 
estrogens declines (46; 216).  
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 One of the most visible changes associated with menopause is weight gain 
accompanied by a significant increase in visceral fat.  This link between estrogens and 
weight gain has been demonstrated in both human and animal models (44; 117; 149; 
188).  Significant weight gain and increases in visceral fat mass have been attributed to 
decreased levels of estrogens in post-menopausal females (114; 116; 117; 169; 188).  
However, with the use of hormone replacement therapy (HRT), attenuation of weight 
gain and central obesity is possible (98; 138), suggesting that estrogens play an important 
role in weight maintenance in women.  Unfortunately, studies recently performed as part 
of the Women’s Health Initiative link use of HRT to increased risk of stroke, blood clots, 
heart disease, and cancer (206), suggesting that HRT may be contraindicated in post-
menopausal women.  In contrast, a number of investigations have questioned the validity 
of these findings and called for more extensive research of HRT use (for review see Wise 
2003) (218).  With the equivocal nature of HRT, further research is warranted in 
determining the mechanisms by which estrogens impact weight gain, particularly in the 
visceral region, in post-menopausal females (206).  
 Not only does estrogen status play a role in body composition, it has also been 
demonstrated to impact the onset of the metabolic syndrome (18; 30; 46; 48; 50; 184).  
Post-menopausal women have a 60% chance of developing metabolic syndrome, while in 
age-matched pre-menopausal women, the risk is only 20-30% (151).  Presence of the 
metabolic syndrome is linked to an increased occurrence of coronary heart disease, type 
II diabetes, and other conditions resulting from arterial plaque build-up (55).  According 
to the American Heart Association, metabolic syndrome is defined by the presence of 
three or more of the following criteria: elevated waist circumference, elevated 
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triglycerides, decreased HDL cholesterol, elevated blood pressure, and/or elevated blood 
glucose (71).  The loss of estrogens has been linked to alterations in visceral adiposity, 
blood glucose regulation, and blood triglyceride levels among post-menopausal women 
(11; 18; 30; 50; 177; 184), with HRT reversing many of these negative changes (22; 27).  
Thus, HRT may be a way to prevent deleterious metabolic alterations in post-menopausal 
women.   Furthermore, there are data which would suggest that estrogens provide women 
with a metabolic phenotype that favors lipid utilization over lipid storage (31; 172; 173).   
 While pharmaceutical treatment is often employed in treating many of the health 
problems associated with obesity and metabolic syndrome, the use of exercise as a 
treatment is an effective alternative for most individuals (1; 5; 52).  Properly designed 
exercise programs, along with a balanced diet, can contribute to significant weight loss in 
obese individuals (7; 162).  Furthermore, weight loss through diet and exercise often 
eliminates the presence of obesity-related diseases such as diabetes (92; 192) and 
cardiovascular disease (80; 81; 113).  Regular exercise can also result in significant 
improvements in blood lipid profiles (81; 162) and blood pressure (169).  Overall, 
exercise has been demonstrated as an effective treatment for many of the components of 
metabolic syndrome.  
 Although exercise has been utilized as an effective treatment for metabolic 
syndrome in males, or in pre-menopausal females, little is known about the potential for 
exercise treatment of weight gain and metabolic syndrome which occur in females 
following menopause.  With the current recommendations indicating that females should 
discontinue use of HRT, the use of remedial therapies warrants further investigation.  
Unfortunately, few data exist demonstrating that exercise is an effective intervention in 
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post-menopausal women and it is unclear if exercise is effective at all without concurrent 
use of HRT.  Therefore, the testing of exercise, and its potential interaction with 
estrogens, as a preventative measure in development of chronic conditions accompanying 
menopause, should be further investigated.   
Purpose:  The purpose of this study is three fold: 
1) To explore the effectiveness of voluntary exercise in preventing metabolic 
syndrome associated with the surgical loss of estrogens.   
2) To determine if estrogens are necessary for exercise induced benefits in female 
mice.   
3) To elucidate if molecular and cellular mechanisms known to regulate lipid 
oxidation are up-regulated with exercise training when estrogen levels are 
decreased.  
Specific Aim 1: To determine if voluntary exercise will attenuate the onset of the 
metabolic syndrome in ovariectomized mice and if this effect will be accentuated in 
mice supplemented with 17β-estradiol.  
H1: Ovariectomized mice undergoing voluntary exercise training will have similar 
fat masses to female control mice, but higher masses than ovariectomized mice 
supplemented with 17β-estradiol.   
H2: Ovariectomized mice undergoing voluntary exercise training will have similar 
levels of circulating free fatty acids to control mice, but higher levels than 
ovariectomized mice supplemented with 17β-estradiol. 
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H3: Ovariectomized mice undergoing voluntary exercise training will have similar 
fasting blood glucose levels to control mice, but impaired fasting blood glucose 
levels compared to ovariectomized mice supplemented with 17β-estradiol.  
Specific Aim 2: To determine if voluntary exercise will induce a metabolic 
phenotype in skeletal muscle that encourages lipid oxidation in ovariectomized mice, 
and if this effect will be accentuated with 17β-estradiol supplementation.   
H4: The sedentary ovariectomized mice will have greater amounts of 
intramuscular triglycerides than the exercise-trained ovariectomized mice or 17β-
estradiol-supplemented mice. 
H5: The sedentary ovariectomized mice will have decreased expression levels of 
lipid oxidative genes as compared to the exercise-trained ovariectomized mice or 
17β-estradiol-supplemented mice.   
H6: The sedentary ovariectomized mice will have increased expression levels of 
genes promoting lipid storage as compared to the exercise-trained ovariectomized 
mice or 17β-estradiol-supplemented mice. 
H7: The sedentary ovariectomized mice will have increased phosphorylation of 
ERK1/2 (Thr 202/Tyr 204) in adipose tissue at rest as compared to the sedentary 
SHAM mice and ovariectomized mice supplemented with 17β-estradiol.  The 
exercise-trained SHAM mice and 17β-estradiol-supplemented mice will have 
increased phosphorylation ERK1/2 (Thr 202/Tyr 204) compared to their 
sedentary counterparts.  The exercise-trained OVX mice will have 
phosphorylation levels of ERK1/2 (Thr 202/Tyr 204) similar to sedentary OVX 
mice.  
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METHODS 
Animals: Thirty-two 8-week old C57/BL6 (Harlan) female mice were divided into three 
groups (SHAM, OVX, OVX+E2).  Due to limitations in the number of running wheels 
available, the total number of animals utilized was less than the total of 48 that was 
originally proposed.  One group of mice (n=12) underwent a bi-lateral ovariectomy 
(OVX), a frequently used animal model of menopause (103).  Our lab has previously 
shown that this model decreases the levels of circulating estrogens by 70% within 48 
hours (191).  A second group (n=10) was subjected to a SHAM surgery where they were 
anesthetized, but did not undergo ovariectomy.  The third group (n=10) consisted of 
ovariectomized mice which underwent a second surgery one week after the ovariectomy 
where exogenous estrogen was introduced via implantation of a subcutaneous time-
release pellet (Innovative Research, Sarasota, FL).  This pellet results in the animals 
receiving ~40pg/mL of 17-β estradiol per day, which is similar to levels found in the 
mouse during estrous (142).   
 Mice were given ad libitum access to water and standard rodent chow (Purina 
Laboratory Rodent Diet 5001: 23% protein, 4.5% fat, 6% fiber) and were housed in a 
temperature-controlled room on a 12h light/dark cycle.  The exercise training group was 
placed in cages with voluntary running wheels, while the sedentary group was placed in 
standard mouse cages.  Running activity, including distance run, average speed, and 
running duration was monitored for 8 weeks with a photocell counter interfaced with a 
computer through customized software (Layfayette Instruments, Layfayette, IN).  
However, due to unforeseen circumstance involving the computer, only total running 
distance is reported.  Following the 8-week training protocol, animals were sacrificed and 
 -  - 6
 
tissue (see table 1 below) was collected, snap frozen in liquid nitrogen, and stored at        
-80°C.  Mice were removed from the wheel cages 24 hours prior to sacrifice to account 
for acute effects of exercise, followed by the removal of food 4-5 hours prior to sacrifice. 
Table 1. Tissue samples collected from mice. 
Muscle Tissue: 
L-Gastrocnemius R-Gastrocnemius L-Tibialis Anterior R-Tibialis Anterior 
L-Plantaris R-Plantaris L-Soleus R-Soleus 





Visceral fat pad Spleen Pancreas Brain 
Heart Blood Liver Hippocampus 
 
In order to obtain serum samples, blood was removed from the chest cavity and placed in 
a microcentrifuge tube which was spun at 750g for 30 minutes at room temperature.  The 
serum was drawn off, placed in a fresh tube, and stored at -80°C.  All aspects of this 
study were approved by the University of Maryland Institutional Animal Care & Use 
Committee (IACUC) Review Board (protocol R-06-77). 
PAS staining:  A cryostat was used to cut a 10 µm thick section from each tibialis 
anterior (TA) sample.  The muscle sections were attached to a glycine-coated glass slide, 
which was then placed in a staining dish.  Carnoy’s fixative was added to the dish for 10 
minutes, followed by a gentle rinse with deionized water. The Periodic Acid solution was 
then added to the dish for 10 minutes, again followed by rinsing of the slides with 
deionized water.  Next, Shiff Reagent was added for 5 minutes and deionized water was 
used to wash the samples three times after removal from reagent.  Ascending alcohol 
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solutions (50%, 70%, 80%, 95% x 2, 100% x 2) placed in staining dishes were used to 
dehydrate the samples.  After alcohol dehydration, samples were washed with neoclear 
(Harleco, Darmstadt, Germany) three to four times in a staining dish.  Permount 
(Biomeda, Burlingame, CA) was used to mount coverslips onto the glass slides.  The 
slides were analyzed under a microscope, with fibers containing high levels of glycogen 
appearing pink, red, or purple in color.  The numbers of positive, partially positive, and 
negative fibers were counted and expressed as a percentage of total fibers.  A minimum 
of 50 fibers per muscle were counted. 
Oil-Red-O:    A cryostat was used to cut a 10 µm section of each frozen TA muscle 
sample.  Samples were air dried onto to a glass slide then fixed in formalin for 5 minutes 
followed by a 1-minute wash with tap water.  The slides were then rinsed with 60% 
isopropanol, stained with Oil-Red-O solution for 30 minutes and rinsed with 60% 
isopropanol.  Permount (Biomeda, Burlingame, CA) was used to mount a coverslip onto 
the glass slide.  The slides were analyzed under a microscope and representative pictures 
of triglyceride content were taken for each muscle from each animal.   
Western Blotting of Adipose Tissue: Western blotting was performed in order to analyze 
protein content of total ERK1/2 and p-ERK1/2 (Thr 202/Tyr 204) in visceral fat.  Fat was 
homogenized in Mueller buffer (50 mM Hepes (pH 7.4), 0.1% Triton –X100, 4 mM 
EGTA, 10 mM EDTA, 15 mM Na4P2O7H2O, 100 mM β-glycerophosphate, 25 mM 
NaF, 50 µg/mL leupeptin, 50 µg/mL pepstatin, 40 µg/mL aprotinin, 5 mM Na3VO4, and 
1 mM PMSF) using a mechanical homogenizer, then centrifuged for 10 minutes at 4°C 
and 13,000 rpm.  The supernatant between the fat cake and the pellet was removed using 
a syringe and placed into a separate tube, which was spun once more under the same 
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conditions.  The middle layer was drawn off again and placed in a fresh tube.  Mueller 
buffer was used to create a 1:50 dilution of the sample for a Pierce protein assay where 
protein concentration was determined via absorbance at 562 nm as compared to a 
standard curve.  Equal amounts of total protein were resolved on 10% SDS-PAGE gels 
and transferred to PVDF membranes as previously described (32).  Blots were incubated 
with Ponceau S (Sigma Chemical) to ensure equal loading of the lanes and then blocked 
with 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween (TBS-T).  Membranes 
were probed with antibodies for p-ERK1/2 (Thr 202/Tyr 204; 1:2000), or total ERK1/2 
(1:2000) in a buffer of 5% BSA in TBS-T on a rocker in a cold room overnight.  
Following incubation with the primary antibody, membranes were washed in TBS-T (3 x 
5 min) and then incubated for 1 hour with horseradish peroxidase (HRP)-conjugated 
rabbit secondary antibody (1:1000) in 5% nonfat dry milk in TBS-T.  Next, membranes 
were washed in TBS-T (1 x 10 min, 3 x 5 min), followed by enhanced 
chemiluminescence reagent (ECL) (Pierce, Rockford, Ill).  Following ECL exposure, 
bands were visualized and quantified with GeneSnap and the GeneTools program 
(Syngene, Frederick, Md).   
RNA isolation:  TRIzol reagent (Invitrogen Technologies, San Diego, CA) was used for 
RNA extraction from the quadriceps muscle samples by the guanidine isothiocyanide 
method previously described by Chomczynsky (35).  First, each sample was 
homogenized with 1 mL of TRIzol and placed in a 1.7 mL microfuge tube.  Homogenates 
were incubated for 10 minutes and vortexed periodically.  Next, 0.2 mL of chloroform 
was added to each sample, which was then inverted until the sample became cloudy, 
followed by 10 minutes of gentle rotation.  Tubes were centrifuged at 12,000 rpm for 12 
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minutes at 4°C.  The upper aqueous phase was transferred to a new microfuge tube to 
which was added 0.5 mL of isopropyl alcohol.  Following 10 minutes of gentle rotation, 
tubes were centrifuged at 12,000 rpm for 8 minutes at 4°C.  The supernatant was then 
removed and discarded without disrupting the RNA pellet.  Next, 1.5 mL of 75% ethanol 
was added to each tube, which was vortexed briefly, then incubated at room temperature 
for 5 minutes, then spun at 7500 rpm for 5 minutes at 4°C.  The ethanol was removed 
without disrupting the RNA pellet.  The pellet was air dried until it became semi-
transparent, at which time 50 µL of TE buffer was added.  A 1:50 dilution of each sample 
to TE buffer was placed in another tube.  A UV spectrophotometer was used to measure 
absorbance at 260 and 280 nm.  TE buffer was used to blank the spectrophotometer, then 
absorbance of the 1:50 dilutions was measured for each sample.  The absorbance at 260 
nm was used to calculate the volume of RNA necessary to reverse transcribe for 1 µg of 
RNA in the subsequent RT reaction.  
Reverse Transcription (RT): One µg of total RNA was reverse transcribed for each 
sample with the Applied Biosystems RT kit (Applied Biosystems, Foster City, CA) in a 
20-µL reaction volume at 25°C for 10 min, followed by incubations at 37°C for 120 
minutes and 85°C for 5 seconds. The samples were subsequently stored at 4°C for future 
analyses. 
PCR: PCR was used to analyze mRNA expression levels of Citrate Synthase (CS), 
Glycogen Phosphorylase (GP), Carnitine Palmitoyl Transferase-1 (CPT-1) and Fatty 
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Table 2. Targets for mRNA expression, forward (F) and reverse (R) primers, annealing temperature, and 
cycle number for each target. 
 























In order to optimize the PCR conditions for each target, PCR reactions were conducted at 
20, 25, 30, 35, and 40 cycles.  The PCR products were run out on a 2% agarose gel.  
Optimal cycle number was determined by the cycle number that produced a band that 
was still in the linear range of detection, as shown below. 
  












rimer, Selected cycle # = 25 Figure 1. An example of optimization of PCR conditions for GP.
 
e RT-PCR method using 18S, as an internal standard was used to measure 
expression of metabolic targets listed above by methods previously described (3).  
 were diluted to a concentration of 10 µM with TE buffer.  A master mix was 
with 2.5 µL 10X Taq buffer, 1.5 µL MgCl2, 2.5 µL dNTP, 0.4 µL forward 
0.4 µL reverse primer, 0.2 µL Taq DNA polymerase, 14 µL dH2O, and 2 µL 
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cDNA per reaction.  However, each reaction for CPT-1 also contained 2.5 µL 
dimethylsulfoxide (DMSO) and only 12 µL dH2O.  This created a 25 µL reaction for 
each sample.  PCR was run in a PTC-100 Peltier thermal cycler (MJ Research, Waltham, 
MA) under the following conditions: 
1) 75°C for 10 minutes 
2) 95°C for 30 seconds 
3) X°C for 30 seconds (annealing temp) 
4) 75°C for 30 seconds 
5) X cycles of steps 2-4 (specific for each target) 
6) 75°C for 5 minutes 
After removal from the thermal cyclers, 8ul of Orange G was added to each sample.  
Samples were loaded onto a 2% agarose gel (300 µL SB, 6 g agarose, 15 µL EtBr) along 
with a molecular weight marker, and run at 120V for one hour.  Bands were visualized 
using a camera and Kodak ID software (Kodak, Rochester, NY).  Quantification of bands 
was performed using ImageJ software (Image J, NIH Bethesda, MD).  The ratio of GP to 
CS was used as an indication of energy utilization potential, while the ratio of FAT/CD36 
to CPT-1 served as a measure of lipid storage.   
NEFA Assay: 
 In order to determine levels of non-esterified fatty acid (NEFA) in mouse serum, a 
colorimetric assay was performed (Wako Diagnostics, Richmond, VA).  A standard curve 
was made using supplied NEFA stock solutions.  Tubes were labeled for each sample and 
for all concentrations of the standard curve.  To each tube, 25 µL of sample was added, 
followed by the addition of 1 mL of reagent A.  Contents were mixed well and then 
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incubated for 5 minutes at 37°C.  Following incubation, absorbance was measured at both 
550 nm and 660 nm.  Next, 0.5 mL of reagent B was added to each tube.  Tubes were 
mixed well and incubated for another 5 minutes at 37°C.  After the second incubation, 
absorbance was measured at 550 nm and 660 nm.  Absorbance values at 660 nm were 
subtracted from absorbance values at 550 nm to get final absorbance values.  Absorbance 
value versus concentration was plotted for the standard curve, which resulted in a linear 
relationship.  The linear equation was used with the final absorbance values for each 
sample in order to calculate NEFA levels.    
Blood Glucose Measurement: 
 When animals were sacrificed, 100 µL of blood was placed into a microcentrifuge 
tube and stored at -80°C until analyses were made.  Blood was thawed on ice and 
vortexed just prior to conducting measurements.  Blood glucose was measured using a 
YSI Glucose Analyzer (YSI Life Sciences, Yellow Springs, OH).  The machine was 
calibrated and samples were measured in manual mode.  For each sample, the sipper 
aspirated 25 µL of blood.  In order to get readings in duplicate, measures were taken from 
two separate probes.  Measures were made for each sample with the two probes and 
recorded in mg/dL. 
Statistical Analysis: 
 All data are expressed as means ± SEM.  Statistical significance was determined 
using t-tests (one-tail) with Sigma Stat statistical analysis software (Systat Software Inc., 
San Jose, CA).  All comparisons that were analyzed were based on the specific, 
directional hypotheses described in the proposal.  A p-value ≤ 0.05 was considered 
significant. 




The effects of OVX, exercise training, and 17β-estradiol supplementation on anatomical 
characteristics and markers of metabolic syndrome in 16-week-old C57/Bl6 mice.  The 
average body and tissue weights for animals in each group are summarized in Figure 2 
and Table 3(A-B).  The visceral fat mass in the sedentary OVX group was significantly 
greater compared to all the other groups, with a significant 313% higher value compared 
to the sedentary SHAM animals (p=0.004) (Fig. 2).  Further, voluntary wheel running 
was effective at preventing the increase in visceral fat mass in the OVX mice as 
compared to the sedentary OVX mice (p=0.027).  Supplementation with 17β-estradiol 
prevented any increase in the visceral fat mass of the OVX animals when compared to 
the SHAM animals, with no additional effect of exercise in conjunction with 17-β 
estradiol supplementation.  Body mass of sedentary OVX animals was significantly 
greater than that of sedentary SHAM animals (p=0.044) (Table 3A).  Heart and liver 
weights in the OVX+E  ex group were significantly greater than those of the SHAM sed 
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 Figure 2. Visceral fat mass for each group.  N=5 for SHAM sed/ex, 
OVX+E2 sed/ex groups. N=6 for OVX sed/ex groups.  Values are 
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Table 3 (A-B). Anatomical characteristics.  N=5 for SHAM sed/ex, OVX+E2 sed/ex groups.  N=6 for OVX 
sed/ex groups. Values are presented as means ± SEM.  
 




















































































B) Organ weight 








SHAM sed 0.904±0.063 - 0.102±0.002 - 
SHAM ex 1.075±0.075 0.060 0.109±0.006 0.165 
OVX sed 0.940±0.068 0.356 0.105±0.007 0.382 
OVX ex 0.939±0.059 0.494 0.106±0.002 0.470 
OVX+E2 sed 1.025±0.049 0.084 0.104±0.004 0.390 
OVX+E2 ex 1.088±0.041       0.020    * 0.115±0.004       0.011    * 
 
 
The effects of OVX and17β- estradiol supplementation on voluntary wheel-running 
activity.  The average distances run per day for the SHAM, OVX, and OVX+E2 mice in 
the wheel-running groups are shown in Figure 3.  Ovariectomy resulted in a significant 
73% decrease in running distance compared to the SHAM animals (p=0.0005). 
 Supplementation of the OVX animals with 17β-estradiol resulted in a 110% increase in 
running distance compared to the OVX group (p=0.016), although the distances were still 
significantly less than the SHAM group (p=0.004). 
 
 




































Figure 3. Average distance run per day for each group. N=5 for SHAM and OVX+E2 
groups, N=6 for OVX group. Data is presented as means ± SEM.  
*Indicates significantly different from SHAM group, #indicates significantly different 
from OVX group (p<0.05). 
 
 
The effects of OVX and estradiol supplementation on blood glucose and NEFA levels.  
Average fasted non-esterified free fatty acid (NEFA) and blood glucose levels are 
summarized in Table 4.  SHAM sedentary animals were not significantly different 
compared to any other group.  However, NEFA levels in OVX sedentary mice were 
significantly greater than NEFA levels in SHAM exercised mice (p=0.05).  Further, when 
NEFA levels from sedentary and exercised groups were combined for each condition 
(SHAM, OVX, OVX+E2), the OVX mice had significantly greater NEFA levels than 
SHAM mice (p=0.021), but were not significantly different from OVX+E2 mice. 
Blood glucose was higher in OVX sedentary mice as compared to SHAM 
sedentary (p=0.031), OVX+E2 sedentary (p=0.031), and OVX exercised (p=0.031) mice 
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Table 4. Fasted NEFA and glucose levels in blood.  N=5 for SHAM sed/ex, OVX+E2 sed/ex groups.  N=6 
for OVX sed/ex groups. Values are presented as means ± SEM.  P-values are presented for values as 
compared to the SHAM sed group. 
 
Group Average NEFA 
(mmol/L) 
p value Average Blood 
Glucose (mg/dl) 
p value 
SHAM sed 0.1312±0.0187 - 188.5±14.48 - 
SHAM ex 0.1129±0.0219 0.271 198.3±15.27 0.327 
OVX sed 0.1616±0.0330 0.094 221.42±20.07   0.031* 
OVX ex 0.2057±0.0517 0.121 176.42±8.68 0.321 
OVX+E2 sed 0.1320±0.0230 0.490 177.1±9.09 0.329 
OVX+E2 ex 0.1777±0.0311 0.110 195.9±19.4 0.336 
 
Glycogen staining in the TA muscle of each group.  An example of how individual fibers 
were categorized is shown in Figure 4A.  Results of PAS staining are shown in Figure 4B 
as the percentage of total fibers which were glycogen positive (+/+), partially positive 
(+/-), and negative (-/-).  The percentage of positive fibers and partially positive fibers 
was significantly greater in exercised animals versus sedentary animals for each 
intervention.  The percentage of negative fibers was significantly lower in exercised 
animals versus sedentary animals for each intervention (p<0.001).  OVX sedentary mice 
had a significantly lower percentage of positive fibers as compared to SHAM sedentary 
mice (p=0.017).  The percentage of positive and partially positive fibers was increased, 
and the percent of negative fibers decreased in the OVX exercised group compared to the 
OVX sedentary group (p=0.003, p=0.002, p=0.0004, respectively).  Further, no 
differences were detected between the OVX exercise group and the SHAM sedentary 
group.  No differences were detected between the OVX+E2 sedentary and the SHAM 
sedentary groups.  OVX+E2 exercised animals had a greater percentage of partially 
positive fibers and a decreased percentage of negative fibers as compared to OVX+E2 
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sedentary animals (p=0.03, p=0.05, respectively).  The percentage of positive and 
partially positive fibers were increased, and the percentage of negative fibers decreased in 
the OVX+E2 exercised animals compared to SHAM sedentary animals (p=0.05, p=0.02, 










Figure 4.   
A) Example of PAS stain quantification.  +/+ indicates fiber counted as positive, +/- indicates fiber 
counted as partially positive, -/- indicates fiber counted as negative.    
B) Results of PAS staining for each group.  N=4 for SHAM sed/ex, OVX+E2 sed.  N=3 for OVX+E2 ex 
group.  N=5 for OVX sed/ex groups.  Values indicate the % of fibers counted (+/+, +/-, -/-) with a 
minimum of 50 total fibers. Presented as average %  ± SEM.  *Indicates significantly different from 
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Triglyceride staining in the TA muscle of each group.  TA cross-sections stained with 
Oil-Red-O were qualitatively observed under a light microscope.  In the SHAM 
sedentary animals, there was minimal presence of triglyceride, indicated by the absence 
of red pigment, as shown in Figure 5.  In the SHAM exercise group, there was frequent 
appearance of triglyceride, indicated by the dark red droplets (Figure 5).  The OVX 
sedentary animals exhibited large volumes of red droplets.  Exercised OVX animals also 
had large amounts of dark red droplets (Figure 5).  The 17β-estradiol-supplemented, 
sedentary mice had fibers that were low in droplet presence.  In the OVX+E2 exercise 
group there was a frequent appearance of red droplets in the muscle (Figure 5). 




         OVX sed                       OVX ex 
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Figure 5. Example of Oil-red-O stain for SHAM sed/ex, OVX sed/ex, and OVX+E2 sed/ex animals.  
Dark red color indicates presence of intramuscular triglyceride. 
 
 
Metabolic gene expression in the quadriceps muscle. Expression levels of GP and CS 
were not different among any of the groups (Figures 6A-B).  Further, the ratio of GP:CS 
did not yield any significant differences in gene expression (Figure 6C). 
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 4a. Relative expression of normalized GP.  N=5 in SHAM sed/ex,



















Figure 4b. Relative Expression of normalized CS. N=5 in SHAM  sed/ex, 
OVX+E2 sed/ex groups. N=6 in OVX sed/ex groups.  Values are presented 
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Figure 6B. Relative expression of normalized 
CS. N=5 for SHAM sed/ex, OVX+E2 sed/ex 
groups.  N=6 for OVX sed/ex groups. Values 
are presented as means ± SEM. 
Fi ed 
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Figure 4c. Ratio of  GP:CS.  N=5 in SHAM sed/ex, OVX+E2 sed/ex 
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Figure 6C. Ratio of GP:CS. N=5 for SHAM 
sed/ex, OVX+E2 sed/ex groups.  N=6 for OVX 










No differences in expression levels of FAT/CD36 or CPT-1 were found between any 
groups (Figure 7A-B).  The ratio of FAT/CD36:CPT-1 did not exhibit any significant 
differences between groups (Figure 7C). 
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ure 5a. Relative expression of normalized CD36. N=5 in SHAM sed/ex,
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Figure 5 b. Relative expression of normalized CPT-1.  N=5 in SHAM sed/ex, 




































SHAM       SHAM OVX        OVX OVX+E2      OVX+E2
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Figure 5c. Ratio of CD36:CPT-1. N=5 in SHAM sed/ex, OVX+E2 sed/ex groups. 

























 Figure 7C. Ratio of FAT/CD36:CPT-1. N=5 
for SHAM sed/ex, OVX+E2 sed/ex groups.  
N=6 for OVX sed/ex groups. Values are 
presented as means ± SEM. 
Figure 7B. Relative expres ion of norm lized 
CPT-1. N=5 for SHAM sed/ex, OVX+E2 sed/ex 
groups.  N=6 for OVX sed/ex groups. Values 
are presented as means ± SEM. 
Figure 7A. Relative expression of normalized    
FAT/CD 36. N=5 for SHAM sed/ex, OVX+E2 
sed/ex groups.  N=6 for OVX sed/ex groups. 











MAPK phosphorylation in adipose tissue from each group.  Representative blots for 
phosphorylated and total ERK1/2 are shown in Figure 8.  Phosphorylation of ERK1 (p-
ERK1) was significantly greater in the sedentary OVX mice as compared to all other 
groups (p<0.05) (Figure 9).  When normalized to total ERK1, differences were detected 
between the sedentary SHAM and OVX mice (p=0.016) and between the OVX and 
OVX+ E2 sedentary mice (p=0.037) (Figure 10).   
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Figure 7. Relative phosphorylation of p-ERK1 was higher in the OVX sedentary 
group. N=5 in SHAM sed/ex, OVX+E2 sed/ex groups. N=6 in OVX sed/ex groups.  
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Figure 8. Phosphorylation of ERK1 normalized to total ERK1. N=5 in SHAM 
sed/ex, OVX+E2 sed/ex groups. N=6 in OVX sed/ex groups.
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Figur 10. Ph sph rylatio  of ERK1 normalized to total ERK1. N=5 for SHAM 
sed/ex, OVX+E2 sed/ex groups.  N=6 for OVX sed/ex groups.  
#Indicates significantly different from SHAM sed (p=0.016) 
$Indicates significantly different from OVX sed (p=0.037) 
Figure 9. Absolute phosphorylation of ERK1 was higher in the OVX sed group. 
N=5 for SHAM sed/ex, OVX+E2 sed/ex groups.  N=6 for OVX sed/ex groups.  
*Indicates significantly different from all groups (p<0.05) 
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Phosphorylation of ERK2 (p-ERK2) was also significantly greater in the 
sedentary OVX mice as compared to all other groups (p<0.05), (Figure 11).  When 
normalized to total ERK1, differences were detected between the sedentary SHAM and 




































Figure 9. Relative phosphorylation of ERK2 was higher in the OVX sedentary 
group. N=5 in SHAM sed/ex, OVX+E2 sed/ex groups. N=6 in OVX sed/ex 
groups.  Data is presented as means ± SEM. 
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Figure 2. Phosphorylation of ERK2 normalized to total ERK2. N=5 for SHAM sed/ex, 
OVX+E2 sed/ex groups.  N=6 for OVX sed/ex groups.  
#Indicates significantly different from SHAM sed (p<0.05) 
Figure 11. Absolute phosphorylation of ERK2 was higher in the OVX sed group. N=5 
for SHAM sed/ex, OVX+E2 sed/ex groups.  N=6 for OVX sed/ex groups.  
*Indicates significantly different from all groups (p<0.05) 
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Discussion 
 This study demonstrates that 10 weeks after undergoing ovariectomy surgery 
(OVX) mice present with significantly elevated levels of blood glucose, NEFA, and 
increased visceral fat mass compared to SHAM animals.  Providing the OVX mice with a 
voluntary running wheel significantly attenuated the increase in blood glucose and 
visceral fat mass when compared to the sedentary SHAM mice even though the OVX 
mice ran significantly less than active SHAM mice.  Supplementation with 17β-estradiol 
did not completely recover running distances in the OVX mice, but did prevent changes 
in blood glucose, NEFA, and visceral fat mass.  ERK1/2, a regulator of HSL-mediated 
lipolysis, was increased in adipose tissue of sedentary OVX mice as compared to 
sedentary SHAM mice.  Both exercise and 17β-estradiol supplementation in the OVX 
mice returned ERK1/2 phosphorylation levels to that of the SHAM mice.  Exercise in 
combination with 17β-estradiol supplementation did not result in further reductions in 
ERK1/2 phosphorylation.  PAS staining of individual fibers in the TA muscle indicated a 
decrease in glycogen storage in sedentary OVX mice as compared to sedentary SHAM 
mice.  Voluntary wheel running increased the percentage of fibers positive for glycogen 
in all groups, however, minimal differences were detected between active groups.  The 
appearance of red droplets, indicative of IMTG, was frequently detected in all active 
groups and sedentary OVX mice.  In contrast, sedentary SHAM and OVX+E2 mice had 
minimal appearance of red droplets.  In spite of changes in PAS and Oil-Red-O staining, 
no changes in mRNA expression of CPT-1, FAT/CD36, CS, or GP in skeletal muscle 
were detected between any of the groups.   
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Ovariectomy induces the metabolic syndrome 
 Based on the findings of this study, it appears that after 10 weeks of ovariectomy, 
mice developed symptoms indicative of the metabolic syndrome.  In particular, OVX 
mice had increased central obesity, increased blood glucose levels, and signs of 
dyslipidemia compared to the SHAM animals.  Other studies have observed similar 
changes in fat mass (64), blood glucose (17), and blood lipid profile (131) in OVX mice.  
Based on these findings, it appears that the ovary plays a role in fatty acid dynamics (See 





























Figure 13. Role of the ovary and ovarian hormones in fatty acid dynamics.  
 However, in line with previous studies (60; 61; 100), 17β-estradiol 
supplementation prevented the increases in visceral fat mass, blood glucose, and NEFA 
levels in OVX mice.  D’Eon et al. found increased levels of serum free fatty acids (FFA) 
following fasting in OVX mice, which was successfully attenuated with 17β-estradiol 
supplementation (44).  Blood glucose levels in mice 13 weeks following ovariectomy 
were significantly increased compared to both SHAM and 17β-estradiol-supplemented 
mice (122).  Many studies have demonstrated an increase in fat mass in mice following 
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ovariectomy (33; 41; 43; 96; 188), as well as an attenuation of fat accumulation when 
OVX mice are supplemented with 17β-estradiol (68; 134; 153; 188).  Thus, these data 
suggest that natural decreases in 17β-estradiol during the onset of menopause may 
mediate some of the documented changes in metabolic parameters that occur in aging 
women.    
 Voluntary wheel running attenuated increases in visceral fat mass and blood 
glucose levels in OVX mice.  This finding is particularly interesting considering the OVX 
animals ran 73% less than the SHAM mice and 53% less than the OVX+E2 mice.  So, 
even reduced levels of physical activity were effective at preventing metabolic changes in 
these mice.  Shinoda et al. demonstrated that forced treadmill running improves body 
composition in OVX rats over a similar duration of time.  However, the running protocol 
employed by Shinoda et al. was extremely vigorous compared to voluntary wheel 
running, with rats running up to 60 minutes at 26m/min and 10% slope 5 times per week 
over the 8-week study (188).  Both voluntary wheel running and 17β-estradiol 
supplementation attenuated onset of metabolic syndrome in OVX mice, however, there 
was no additive effect of the two treatments.  The results suggest that low volumes of 
physical activity are just as effective as HRT in preventing the metabolic syndrome after 
the loss of ovarian hormone function.   
Elevated NEFA levels suggest active lipolysis in OVX animals 
 When sedentary and exercised animals were pooled, the OVX animals exhibited 
increased levels of circulating NEFA.  Previous studies suggest that ERK1/2 enhances 
HSL activity and subsequently enhances lipolysis (69; 93).  In sedentary OVX animals 
ERK1/2 phosphorylation was greater than all other groups.  Phosphorylation of ERK1/2 
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at Thr 202/Tyr 204 is necessary for complete catalytic activation of ERK1/2.  
Phosphorylated ERK1/2 can phosphorylate HSL at Ser600, which increases HSL activity 
and subsequently enhances lipolysis (193).  In the sedentary OVX animals, NEFA levels 
were elevated, thus, an increase in factors contributing to lipolysis, such as ERK1/2 
phosphorylation would be expected.  Voluntary wheel running, as well as 17β-estradiol 
supplementation reduced ERK1/2 phosphorylation to levels equivalent to SHAM 
animals.  Thus, this finding does not explain why the active OVX animals had elevated 
NEFA in that voluntary wheel running was not successful at decreasing ERK1/2 
phosphorylation.  At this time, there is no commercially available antibody to determine 
the phosphorylation status of HSL600 in our samples.  Thus it is unclear how HSL is 
affected by this change in ERK1/2 phosphorylation.  It is possible that another factor, 
such as AMPK, contributed to changes in lipolysis and thus increased NEFA levels in 
exercised OVX animals.  For example, other studies have shown AMPK to be activated 
and to exert a significant effect on lipolysis in adipose tissue taken from physically active 
animals (107; 110; 150).  While many attempts were made to determine AMPK 
phosphorylation, the presence of AMPK was not detectable in adipose tissue in this 
study.  This may be in part due to the fact that our measures were made in tissue from 
animals at rest, while other studies have measured AMPK in adipose tissue immediately 
after exercise (107; 110; 150).  Further, regulation of HSL occurs by phosphorylation at 
multiple sites.  The Ser563, Ser659, and Ser 660 sites are phosphorylated by Protein 
Kinase A (PKA) (29).  Phosphorylation at these sites is additive in nature to HSL 
activation (47), and these remaining sites will need to be measured in these samples.  In 
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addition, adipose tissue glycerol lipase (ATGL) was recently discovered and it is possible 
that ATGL contributes to changes in these animals (220).   
 While the role of ERK1/2 in adipose tissue lipolysis in OVX mice may be 
uncertain, it is clear that changes in ovarian hormone status affected the phosphorylation 
status of ERK1/2, and the phosphorylation status was reversed by voluntary wheel- 
running and 17β-estradiol supplementation.  
No differences in metabolic gene expression in the skeletal muscle were detected 
 Expression levels of CPT-1, FAT/CD36, GP and CS were not significantly 
different among any of the groups.  CPT-1 promotes the oxidation of fat and decreases 
esterification of FFA (26).  Previous studies have shown that CPT-1 expression increases 
with obesity (154), thus, it was somewhat surprising that no differences were detected in 
the OVX sedentary animals.  However, because no gender differences have been detected 
in CPT-1 expression (20), perhaps ovarian hormones do not contribute to regulation of 
CPT-1 expression.  Further, it is possible that the mice in this study were not obese for a 
long enough period of time to bring about changes in CPT-1 expression at the mRNA 
level in skeletal muscle.   
   FAT/CD36 plays an important role in FFA uptake at the level of the plasma 
membrane (108; 205).  Even though the OVX mice appear to have increased fat storage, 
these mice did not exhibit differences in mRNA expression of FAT/CD36 compared to 
the SHAM group.  In humans, it has been shown that short-term exercise training results 
in changes in FAT/CD36 expression (84).  However, in this study, long-term exercise 
training failed to induce any changes in FAT/CD36 expression in muscle (183).  This 
may indicate that mRNA changes in FAT/CD36 occur quickly, allowing for any 
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adaptations in protein expression to occur.  Recently, it has been suggested that 
contraction-induced translocation of FAT/CD36 to the mitochondrial membrane is a 
significant contributor to FFA oxidation (73).  This would suggest that the critical factor 
affecting FAT/CD36 is localization and not expression, thus, it is necessary to perform 
follow-up experiments at the protein level.   
 Citrate Synthase (CS) is an indicator of oxidative capacity which also promotes 
the oxidation of fat and decreases esterification of FFA (26).  In spite of increased fat 
storage, no differences in CS expression in OVX mice compared to SHAM mice were 
found.  Roepstorff et al. found gender differences to exist in CS protein activity, but no 
differences in CS mRNA expression (171).  This may indicate that CS expression is 
regulated at the level of protein translation.  Therefore, follow-up experiments at the 
protein level should be performed.  
GP contributes to carbohydrate utilization by catalyzing the breakdown of 
glycogen for glycolysis (89).  Even though the sedentary OVX mice appear to have 
decreased glycogen storage, these mice did not exhibit differences in GP mRNA 
expression compared to the SHAM group.  Interestingly, none of the active groups 
demonstrated changes in GP mRNA.  Other studies utilizing endurance exercise training 
have also failed to demonstrate changes in GP expression at the mRNA level (118).  It 
was predicted that OVX mice would show differences in GP mRNA expression since 
other studies have found gender- and obesity-related differences in GP activity (4; 88).  
As with CS, this may suggest that follow-up experiments at the protein level should be 
performed to detect changes in GP activity. 
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 It was somewhat surprising not to detect differences in CPT-1, FAT/CD36, CS, or 
GP mRNA expression based on the PAS and Oil-Red-O staining results in the TA muscle 
from the different groups.  Ovariectomy resulted in a significantly lower percentage of 
PAS positive fibers as compared to SHAM sedentary mice, indicating a potential change 
in glycogen dynamics in the muscle.  Exercise resulted in an increased percentage of PAS 
positive and partially positive fibers, and a decrease in the percentage of negative fibers 
as compared to the sedentary animals in all groups. Therefore, the ability of exercise to 
increase glycogen storage was not defective in any group.  Based on these results, it 
appears that OVX results in a net loss in glycogen positive fibers, suggesting that 
glycogen is not stored effectively or it is utilized at a higher rate in OVX mice than in the 
SHAM animals.  Beckett et al. found a similar decrease in muscle glycogen content 
following ovariectomy (14).  Interestingly, exercise is effective at restoring the number of 
glycogen positive fibers in OVX animals to a level equal to that of SHAM animals.  
Thus, exercise fixed the impaired glycogen storage found in sedentary OVX animals.  
Both exercise and 17β-estradiol supplementation was effective at increasing the number 
of glycogen positive fibers in the OVX animals.  
 In addition to differences in glycogen levels, OVX animals exhibited a high 
frequency of Oil-Red-O staining in the muscle, which indicates that the muscle is storing 
lipid.  It is unclear whether this excess storage is due to a failure to oxidize the lipid.  CS 
mRNA expression would suggest that oxidative capacity may not be reduced in these 
animals, as no differences in expression were detected.  However, it is possible that 
measurement of CS at the protein level would be more effective at detecting differences.  
Oil-Red-O staining resulted in high amounts of red droplets in the SHAM, OVX+E2, 
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OVX exercised groups, as well as the OVX sedentary group, and small amounts of red 
droplets in the SHAM and OVX+E2 sedentary groups.  This would suggest that exercise 
and ovariectomy may result in increased uptake of FFA into the muscle.  IMTG content 
in response to exercise training has been widely studied, with endurance exercise training 
resulting in increased levels of IMTG in the muscle (65), as well as increased ability to 
oxidize IMTG (65; 163).  The high amounts of red droplets in the SHAM and OVX+E2 
exercised groups as compared to their sedentary counterparts are thus in line with 
previous findings.  Obesity results in increased uptake of FFA into the muscle as well 
(66; 130).  However, the ability to oxidize IMTG may be impaired (144).  The OVX mice 
in this study displayed centripetal obesity, thus, the high amount of red droplets in the 
sedentary OVX animals would be expected and may be indicative of a reduced oxidative 
capacity of the muscle.    
 While the Oil-Red-O findings are in line with previous studies, there is a 
disconnect with the mRNA expression results within this study.  Measurement of both 
CPT-1 and FAT/CD36 mRNA expression indicated no differences between groups.  An 
increase in FAT/CD36 would be expected to accompany increased IMTG, as FAT/CD36 
contributes to FFA uptake into muscle cells.  Further, in animals capable of increased 
oxidation of IMTG, such as the SHAM exercise trained group, an increase in CPT-1 
expression would be expected, as CPT-1 regulates transport of FFA into the mitochondria 
for oxidation.  However, as previously discussed, these expected differences may not 
have been observed since FAT/CD36 may be regulated through post-translational 
modification (73; 171).  Therefore, protein expression or protein activity, rather than 
mRNA expression, should be measured.     
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Future Directions 
There are a few areas in which additional experiments should be performed in 
order to expand upon the findings of this study.  While the lack of differences in mRNA 
expression is understandable given the results of other studies, targets could be measured 
at the protein level, or translocation could be measured to test for differences in activity.  
To test the functional effects of changes in ERK1/2 phosphorylation, downstream 
activation of targets (i.e., HSL, ATGL) should be measured.  Recent pilot data indicates 
that ATGL expression, which promotes lipolysis and contains 2 amino acid residues 
capable of phosphorylation by ERK1/2, is elevated in exercised SHAM and OVX mice, 
as well as OVX sedentary mice.  These data suggest that active lipolysis is increased in 
OVX mice.  The increase in ATGL expression in the SHAM mice indicates lipolysis is 
occurring during exercise, however, there is most likely an increase in fat oxidation as, 
well which is absent in the OVX mice.  Clearly, more data will need to be collected to 
further clarify these findings. 
Overall Conclusions  
It appears that both voluntary wheel running and 17β-estradiol supplementation 
are effective in preventing symptoms of the metabolic syndrome and changes in cellular 
signaling of adipose tissue in OVX mice.  However, in light of the Women’s Health 
Initiative (WHI), the question of hormone replacement safety arises.  Two of the 17β-
estradiol-supplemented mice died of unknown causes during this study.  Further, upon 
sacrifice, two mice in the OVX+E2 group had enlarged bladders, a side effect which has 
been found in other labs as well (personal communication with Dr. Dawn Lowe).  The 
results of studies from WHI suggest that HRT increases a woman’s risk of stroke, blood 
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clots, heart disease, and certain cancers.  With the efficacy of even low volumes of 
voluntary wheel running in preventing obesity and metabolic syndrome following ovarian 
hormone loss, exercise should be suggested as an alternative to HRT.   
 When comparing the results to the original hypotheses, some findings confirmed 
the hypotheses, and some findings refuted the hypotheses.  Comparisons between the 
hypotheses and results are shown below.  
 
H1: Ovariectomized mice undergoing voluntary exercise training will have similar 
fat masses to female control mice, but higher masses than ovariectomized mice 
supplemented with 17β-estradiol.   
 The findings of this study supported the hypothesis that OVX exercised mice 
would have similar fat masses to female control mice.  However, OVX exercised mice 
did not have higher fat masses than OVX+E2 mice. 
H2: Ovariectomized mice undergoing voluntary exercise training will have similar 
levels of circulating free fatty acids to control mice, but higher levels than 
ovariectomized mice supplemented with 17β-estradiol. 
 The findings refute this hypothesis, in that exercise training did not decrease 
NEFA levels in OVX mice.  
H3: Ovariectomized mice undergoing voluntary exercise training will have similar 
fasting blood glucose levels to control mice, but impaired fasting blood glucose levels 
compared to ovariectomized mice supplemented with 17β-estradiol.  
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 The findings support the hypothesis that OVX exercised mice would have similar 
fasting blood glucose to control mice.  However, fasting blood glucose levels in the OVX 
exercised mice were not impaired compared to OVX+E2 mice.  
H4: The sedentary ovariectomized mice will have greater amounts of intramuscular 
triglycerides than the exercise-trained ovariectomized mice or 17β-estradiol-
supplemented mice. 
 Due to qualitative, rather than quantitative analysis of Oil-Red-O staining, this 
hypothesis cannot be analyzed.  While quantitative comparisons of groups cannot be 
made, visually it appeared that muscle tissue from the SHAM sed, OVX sed, OVX ex, 
and OVX+E2 ex groups all contained large amounts of IMTG based on the frequent 
appearance of red droplets.  
H5: The sedentary ovariectomized mice will have decreased expression levels of lipid 
oxidative genes as compared to the exercise-trained ovariectomized mice or 17β-
estradiol-supplemented mice.  
 The findings refuted this hypothesis, as no differences in expression of lipid 
oxidative genes were found between any groups.   
H6: The sedentary ovariectomized mice will have increased expression levels of 
genes promoting lipid storage as compared to the exercise-trained ovariectomized 
mice or 17β-estradiol-supplemented mice. 
 The findings refuted this hypothesis, as no differences in expression of genes 
promoting lipid storage were found between any groups.   
H7: The sedentary ovariectomized mice will have increased phosphorylation of 
ERK1/2 (Thr 202/Tyr 204) in adipose tissue at rest as compared to the sedentary 
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SHAM mice and ovariectomized mice supplemented with 17β-estradiol.  The 
exercise-trained SHAM mice and 17β-estradiol-supplemented mice will have 
increased phosphorylation ERK1/2 (Thr 202/Tyr 204) compared to their sedentary 
counterparts.  The exercise-trained OVX mice will have phosphorylation levels of 
ERK1/2 (Thr 202/Tyr 204) similar to sedentary OVX mice.  
 As predicted, ERK1/2 phosphorylation was increased in the sedentary OVX mice 
compared to the sedentary SHAM and OVX+E2 mice.  Also, OVX exercised and 
sedentary groups did demonstrate ERK1/2 phosphorylation levels that were not 
significantly different.  However, the exercised SHAM and OVX+E2 mice did not 
increased ERK1/2 phosphorylation compared to their sedentary counterparts.   
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REVIEW OF LITERATURE 
 
The purpose of this review of literature is to examine the role of exercise and 
estrogens in preventing obesity and the metabolic syndrome in post-menopausal 
females.  
Obesity: 
 The increased incidence of obesity and obesity-related conditions has placed 
significant strain on individual health, the medical community, and the economy alike. 
The most recent figures from the Center of Disease Control estimate 65% of adults, and 
15% of children in the United States are overweight, with 30% falling in the category of 
obese (1).  Along with the increased incidence of obesity, the relative risk for Type II 
diabetes and cardiovascular disease (CVD) has risen dramatically in obese individuals 
(55-57; 102; 196).  Android, or centripetal obesity is of particular concern, since it is 
highly correlated with the development of obesity-related conditions.  Finally, the 
treatment of obesity-related conditions has placed a significant burden on the economy, 
with an estimated $122.9 billion spent annually (CDC), thus, the physiological and 
economic costs of obesity are having a significant impact on American society.   
Obesity-related conditions:  
Studies have linked visceral fat accumulation to an increase in occurrence of Type 
II diabetes, cardiovascular disease, and risk of myocardial infarction in both men and 
women (219).  Taken together, these conditions which have been attributed to obesity 
have been termed the metabolic syndrome.  On the surface, obesity has been dubbed the 
major cause of the metabolic syndrome, however, the underlying mechanisms responsible 
for the associated metabolic changes are an increase in visceral adiposity and insulin 
 -  - 36
 
resistance (5; 71; 167).  Many different groups, including the International Diabetes 
Federation (IDF), World Health Organization (WHO), and Adult Treatment Panel III 
(ATP III), have developed lists of factors used to diagnose the presence of the metabolic 
syndrome.  The criteria set forth by the IDF and WHO are most commonly used for 
diagnosis.  For diagnosis of the metabolic syndrome under the IDF criteria, waist 
circumference must be greater than or equal to 80 cm, indicating central obesity, along 
with 2 of the 4 following criteria: 
1) Elevated triglycerides (greater than or equal to 1.7 mmol/L) 
2) Low HDL cholesterol (less than 1.29 mmol/L) 
3) Elevated blood pressure (systolic greater than or equal to 130 mmHg or 
diastolic greater than or equal to 85 mmHg) 
4) Elevated fasting plasma glucose (greater than or equal to 5.6 mmol/L) 
In order to be diagnosed with the metabolic syndrome with the WHO criteria, a patient 
must exhibit diabetes mellitus, decreased glucose tolerance, increased fasted blood 
glucose or insulin resistance, plus two of the following criteria:  
1) Blood pressure greater than or equal to 140/90 mmHg 
2) Dislipidemia (triglycerides greater than or equal to 1.695 mmol/L and/or high 
 density lipoprotein cholesterol (HDL-C) less than or equal to 1.0 mmol/L),  
3) Central obesity (waist:hip ratio greater than 0.85, and/or body mass index 
(BMI)  greater than 30 kg/m2, and  
4) Microalbuminuria (urinary albumin excretion ratio greater than or equal to 20 
 mg/min or albumin:creatine ratio greater than or equal to 30 mg/g) 
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Age, genetic predisposition, physical inactivity, diet, and possibly hormonal status (168) 
in females all contribute to an increased risk for the development of the metabolic 
syndrome (170).   
Path from obesity to metabolic syndrome: 
On a cellular level, various theories have been developed to explain the 
progression from obesity to the onset of the metabolic syndrome.  Obesity results in 
increased amounts of white adipose tissue (WAT) and greater amounts of visceral fat 
than subcutaneous fat (132).  WAT has a large capacity to store lipids, and this increase 
in lipid storage has a pathophysiological effect as well (211).  Obese patients demonstrate 
low-grade inflammation that originates from WAT, and is characterized by an increase in 
inflammatory markers such as interleukin 6 (IL-6), and tumor necrosis factor alpha 
(TNF-α) (13; 210).  These markers have local effects on the WAT, as well as systemic 
effects that may contribute to insulin resistance (202).  TNF-α contributes to insulin 
resistance by inducing phosphorylation of serine residues on the insulin receptor 
substrate-1 (IRS-1) protein, thus preventing interaction with the insulin receptor β 
subunit, and disrupting the insulin signaling pathway (13).  IL-6 interferes with the signal 
transduction mechanisms involved in insulin signaling, although the mechanism of action 
is unknown (12).  The secretion of IL-6 is greater from visceral adipose tissue than 
subcutaneous adipose tissue (12) and serves as a major marker for cardiovascular 
problems such as atherosclerosis (182) and coronary heart disease (12), which are part of 
the metabolic syndrome.  However, the role of IL-6 is controversial because it also 
increases with exercise and has been suggested to increase glucose uptake by activating 
AMPK (128; 152; 179).  By increasing levels of inflammatory mediators which 
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contribute to insulin resistance and cardiovascular disease, obesity can result in 
development of the metabolic syndrome (101; 109; 146).   
 
The decline in circulating estrogens accompanying menopause plays a strong role in 
metabolic syndrome onset in post-menopausal females.  While many studies have 
addressed the metabolic syndrome from a mechanistic standpoint in males and pre-
menopausal females, much work remains in order to understand the metabolic 
syndrome in post-menopausal females.   
 
Formation of the estrogens:  
 Estrogens are steroid hormones which operate as the primary sex hormones in 
females.  Three major types exist, estradiol, estriol, and estrone, with 17β-estradiol the 
predominant form present in pre-menopausal females (21).  All estrogens begin as 
androgens and are converted to estrogens via enzymatic action of aromatase.  During 
steroidogenesis, cholesterol is converted to pregnenolone by cholesterol side chain 
cleavage enzyme, followed by the conversion of pregnenolone to androstenedione 
through a series of enzymatic reactions.  Androstenedione is then either converted to 
estrone by aromatase, or to testosterone by 17-β hydroxysteroid dehydrogenase (17- β 
HSD).  Aromatase then converts the testosterone to estradiol (166) (See Figure 13 
below).   
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Figure 14. Formation of estrogen, estrone, and progesterone (166). 
 
Function of the estrogens: 
Estrogens play an important role in regulation of numerous physiological 
processes, including the menstrual cycle, the development of female secondary sex 
characteristics, bone growth, etc (129).   
The menstrual cycle is regulated by estrogens and is necessary for reproduction.  
The menstrual cycle consists of three phases: menstruation, the follicular phase, and the 
luteal phase.  The typical menstrual cycle is 28 days long, with day one defined as the 
onset of menses.  During the menstrual cycle, levels of estradiol, progesterone, follicle 
stimulating hormone (FSH), and luteinizing hormone (LH) fluctuate in order for 
ovulation and menstruation to occur (124).  The menstrual cycle continues for females 
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during their reproductive years until the onset of menopause, which is on average at age 
51 (203).  
 In addition to the regulation of the menstrual cycle, estrogens are also important 
in the development of female secondary sex characteristics and bone growth.  Secondary 
sex characteristics are those which distinguish males from females but do not play a role 
in reproduction.  In females, these characteristics include the development of breasts, 
widening of the hips, and increased fat deposit in the thigh and hip region, also known as 
gynoid fat distribution (124).  This fat distribution is typical of females, whereas males 
more often have increased fat in the visceral region, known as android distribution (120).  
Thus, females are commonly referred to as having a “pear” shape, while males have an 
“apple” shape (140).  Many studies have demonstrated that visceral fat accumulation 
places individuals at greater risk for cardiovascular disease (CVD) and the metabolic 
syndrome than fat accumulation in the lower half of the body (28; 42).  Thus, as 
estrogens contribute to gynoid fat distribution, females are typically at decreased risk for 
CVD and the metabolic syndrome based on body shape (28; 67).  
Furthermore, estrogens play a strong role in bone growth during development in 
both males and females.  Due to larger amounts of estrogens, females reach the end of 
their growth spurts, signaled by closing of the epiphyseal plates, more quickly than their 
male counterparts (42).  In addition, estrogens have various effects on the brain, cognitive 
function (for review see Luine 2008) (126), and susceptibility to cancer (155; 186; 187) 
throughout the female lifespan.  It is clear that estrogens are important to function and 
maintenance of many tissues, however, mechanistically, much remains to be discovered.  
Elucidating the mechanisms behind actions of the estrogens would be an important step 
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in understanding the changes which occur during menopause and could potentially lead 
to the development of alternatives to Hormone Replacement Therapy (HRT).  
Menopause: 
 According to the World Health Organization (WHO), menopause is defined as the 
complete cessation of menstruation resulting from loss of ovarian follicular activity.  The 
age at which menopause is reached varies greatly, however, the average woman reaches 
menopause at age 51 (203).  In addition to natural menopause, numerous women 
undergoing hysterectomy to remove the uterus also may have their ovaries removed, 
resulting in a form of surgically-induced menopause (23; 91; 215).  These women 
experience many of the same physiological changes as post-menopausal women (23; 91; 
215).   
All females have a finite number of follicles/oocytes, which are gradually 
exhausted with every menstrual cycle during the reproductive years.  At birth, 1-2 million 
follicles are present, but by the onset of menopause, only about 1,000 remain.  Some of 
the follicles are lost to ovulation, however, most are lost due to degeneration and 
resorption, a process termed atresia.  In young females, follicles respond to increased 
levels of LH and FSH during the menstrual cycle, resulting in ovulation.  As a woman 
nears menopause, the few follicles remaining fail to properly respond to LH and FSH and 
the menstrual cycle becomes irregular.  The stage where the menstrual cycle is irregular, 
but still occurring, is termed perimenopause and covers a time period of 3-10 years prior 
to menopause.  As follicles are the major source of estrogen production, the levels of 
estrogens decline during perimenopause and production almost stops completely once the 
menopausal transition is complete (49; 185; 206).  The transition from perimenopause to 
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post-menopause is defined by a 12-month absence of a menstrual period, at which point 
estrogen levels are very low and FSH levels are high due to decreased negative feedback 
of estrogen (8).     
Menopause and disease risk: 
 This drop in production of estrogens results in the loss of menses, and is 
associated with changes in metabolism, fat distribution, blood lipid profile, and blood 
glucose levels (129; 184).  These conditions are observed in women who go through 
natural menopause, as well as those who undergo hysterectomy (23; 91; 215).  Thus, in 
both natural and surgical menopause, conditions such as the metabolic syndrome, 
cardiovascular disease, and osteoporosis may result as the level of estrogens declines (46; 
216). 
Cardiovascular Disease: 
After menopause, females greatly increase their risk of developing cardiovascular 
disease (CVD) (119; 176).   Pre-menopausal women have an occurrence of coronary 
artery disease (CAD) that is much lower than males (119).  However, after the onset of 
menopause, occurrence of CAD increases significantly (62), accounting for 59% of the 
mortality rate in post-menopausal women (156), and resulting in women equaling the 
mortality rate of age-matched males.  The development and progress of CAD is impacted 
by the sex hormones, in that after menopause, females exhibit changes in blood lipid 
profile, clotting factors, endothelial factors, LDL and HDL cholesterol levels, and 
substrate utilization, all of which may impact the progression of CAD (127; 168; 197).  
While initial studies proved inconclusive (194), the latest updates from the American 
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Heart Association indicate that hypertension is linked to the decrease in sex hormones 
occurring with menopause (123; 164).   
Metabolic Syndrome: 
Not only does hormone status impact female risk for CVD, it also places women 
at an increased risk for development of the metabolic syndrome (34).  With the decrease 
in physical activity and subsequent increase in obesity in recent years, the metabolic 
syndrome has increased in prevalence across many populations.  However, it appears that 
changes in hormone status may contribute to onset of the metabolic syndrome in post-
menopausal women (34).    
In addition to weight gain, post-menopausal women are also at an increased risk 
for developing insulin resistance, another component of the metabolic syndrome (34).  
While some studies conclude that the main cause of insulin resistance in post-menopausal 
women is increased body mass, rather than hormone status, others argue that menopausal 
status plays an important role.  It has been suggested that only a portion of the gradual 
decline in insulin sensitivity following menopause is attributable to increases in visceral 
fat mass (24).  In addition to changes in insulin sensitivity, sex hormones have been 
demonstrated to alter glucose and lipid utilization (168).  These changes in fuel utilization 
may contribute to the weight gain and increased risk for development of diabetes mellitus 
observed in post-menopausal women.  
 While physiological changes which place post-menopausal women at an 
increased risk for developing the metabolic syndrome have been well documented, there 
is no currently accepted way to treat post-menopausal women.  Following the Women’s 
Health Initiative (WHI), Hormone Replacement Therapy (HRT) has been ruled out as a 
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viable treatment for most women after estrogen production declines, due to increased 
occurrence of stroke, blood clots, and heart disease with HRT use.  Thus alternative 
treatments for-post menopausal women should be sought out.  
 
Exercise results in many positive physiological changes that improve overall health. 
In most populations, exercise has been successfully utilized as both a preventative 
measure and a treatment for obesity-related conditions.  However, the effectiveness 
of exercise in attenuating the onset of metabolic syndrome in post-menopausal 
females is currently unknown.  
 
Fuel utilization during exercise:  
 In order to grasp how exercise can prevent and treat the metabolic syndrome, it is 
important to have an understanding of how exercise impacts fuel utilization.  During 
exercise, fat and carbohydrate are the main substrates oxidized for production of ATP 
(207).  Carbohydrates are stored in the form of glycogen in muscle and liver, with plasma 
glucose also significantly contributing to energy during exercise.  Oxidation of muscle 
glycogen is the major source of carbohydrate-produced energy during moderate to high 
intensity exercise (89).  As the duration of exercise increases, glycogen stores become 
depleted and reliance on blood glucose increases (89).  Fat is predominantly stored as 
triacylglycerol in adipose tissue, with some free fatty acids (FFAs) present in the 
bloodstream and a small amount of fat is stored as intramuscular triglycerides (IMTG) in 
muscle (207).  Oxidation of FFAs derived from adipose tissue or IMTG is a major source 
of energy for contracting muscle.  The relative contribution of FFAs and IMTG during 
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submaximal exercise remains controversial, with results of some studies favoring 
increased IMTG oxidation (94; 159; 160) whereas others suggest increased oxidation of 
FFAs (51; 106), regardless, both appear to be used.   
 An increased utilization of fat allows for an attenuated rate of glycogen depletion 
(136; 158) and slowed plasma glucose appearance and oxidation (58; 137; 157).  This 
glycogen sparing from increased fat oxidation can result in an increased endurance 
capacity because glycogen stores are a limiting factor in endurance activity (89).  The 
respiratory exchange ratio (RER) is an indicator of fuel utilization; a value of 0.7 
indicates fat oxidation whereas a value of 1.0 suggests increased carbohydrate oxidation.  
At rest, RER is on average 0.8, increasing to 1 or greater with increasing exercise 
intensity.  According to Brooks and Mercier, the relative exercise intensity where the 
predominant fuel being oxidized switches from fat to carbohydrate is known as the 
“cross-over” point (25).  In untrained individuals, this point is at approximately 50% of 
VO2max (25), although results of some studies suggest that the cross-over point may be 
as high as 65% of VO2max (87).  The point in exercise where oxidation of carbohydrate 
begins to predominate is dependent upon a number of factors, including training status, 
diet, and glycogen availability.  Adaptation to intense endurance exercise may raise the 
crossover point, as suggested by the finding that when subjects underwent 12 weeks of 
high intensity training which raised their VO2max by 26%, there was ~5% reduction in 
RER at the same relative intensity (94).  These results suggest that training decreased the 
utilization of carbohydrate sources.  Diet also plays an important role in fuel utilization 
during exercise.  Diets high in fat have been found to increase oxidation of fat during 
exercise (19; 59; 76; 77; 77; 115).  For example, subjects cycling at 65% of their VO2max 
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while on a high carbohydrate diet had an RER of 0.92, while 7 days of a high fat diet 
resulted in an RER of 0.81 in the same subjects (99).  It is clear that a number of factors, 
including training and diet may impact the cross-over point during exercise.   
Factors Affecting Relative Carbohydrate and Fat Oxidation During Acute Exercise: 
 
Fiber type, size, and capillary density have all been demonstrated to impact fat 
oxidation during exercise.  Slow twitch oxidative Type I fibers, as well as Type IIa, have 
a greater ability to oxidize fat both at rest and during exercise compared to fast twitch 
glycolytic Type IIx/b fibers which are much more reliant on glycolysis at rest and during 
exercise.  Slow twitch fibers exhibit lower absolute maximal force output compared to 
fast twitch fibers, however, slow twitch fibers have increased time to fatigue (133).  
Typically, endurance athletes, such as marathon runners, have a larger percentage of 
Type I and Type IIa fibers, while power athletes, such as sprinters, tend to have more 
Type IIx/b fibers (72). The ability of Type I and Type IIa fibers to store IMTG and 
oxidize a greater amount of fat during exercise is at least partly attributable to increased 
mitochondrial density as compared to Type IIx/b fibers (72).  As mitochondria are the 
machinery for aerobic respiration, increased mitochondrial number corresponds to a 
greater aerobic capacity and oxidation of fat during exercise.  Furthermore, fiber size is 
related to oxidative capacity.  Type I fibers typically have the smallest cross-sectional 
area (CSA), while Type IIx/b fibers have the largest CSA.  In addition to fiber type and 
CSA, capillary density impacts the oxidative capacity of skeletal muscle during exercise 
(2; 89).  Increased capillary density contributes to greater levels of fat oxidation during 
exercise, thus Type I fibers in particular are capillary dense (112).  Having a smaller CSA 
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and increased capillary density is advantageous for oxygen diffusion into the fiber, thus 
increasing the capacity for aerobic respiration (2; 89).  
Analysis of the impact of exercise intensity on fuel oxidation gives further insight 
into the effects of muscle fiber type on carbohydrate and fat oxidation.  During low 
intensity exercise, Type I fibers are preferentially recruited and RER values are relatively 
low, indicating a greater reliance on fat oxidation.  As exercise intensity increases, RER 
increases, indicating greater carbohydrate oxidation, and simultaneously more Type IIx/b 
fibers are recruited (63).  The increase in RER can be attributed, at least in part, to the 
tendency of Type IIx/b fibers to oxidize carbohydrate rather than fat, shifting total 
oxidation from FFAs and IMTG toward glycogen and plasma glucose (63).  The increase 
in glycolysis and glycogenolysis associated with carbohydrate oxidation with increasing 
exercise intensity has been associated with an inhibitory effect on fat oxidation via 
increased malonyl CoA, which inhibits the transfer of long chain FFAs into the 
mitochondria by inhibiting carnitine palmitoyl transferase (217).  
Mitochondrial Enzymes and Exercise Training: 
 Endurance training results in increased numbers of mitochondria within the 
muscle and increased oxidative enzyme expression (82; 83; 139), which includes 
enzymes involved in β-oxidation and lipolysis (31; 160; 204), and mitochondrial 
enzymes, such as enzymes of the Krebs cycle and enzymes associated with oxidative 
phosphorylation (90).   
 Oxidation of fat during exercise is dependent upon a number of enzymes.  
Carnitine palmitoyl transferase (CPT-1) plays a key role in the regulation of fat oxidation.  
CPT-1 is a mitochondrial enzyme which mediates the transport of long chain fatty acids 
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into the mitochondria for oxidation.  In the skeletal muscle of rats where overexpression 
of CPT-1 is induced, fat oxidation is increased and the amount of triacylglycerol present 
in the muscle is decreased.  Thus CPT-1 promotes the oxidation of fat and decreases 
esterification of FFA (26).  Conversely, decreased levels of CPT-1 are seen in skeletal 
muscle from obese subjects compared to lean subjects (154).  Further, no gender-specific 
differences in CPT-1 activity have been observed (20), however, very few studies have 
been performed.  
 Whereas CPT-1 is critical in mitochondrial FFA uptake, Fatty Acid 
Translocase/Cluster of Differentiation (FAT/CD36), plays an important role in FFA 
uptake at the level of the plasma membrane.  Stimulation of muscle via contraction 
results in increased translocation of FAT/CD36 to the plasma membrane, which results in 
an increase in FFA transport into the cell (108; 205).  Exercise training has been shown to 
increase expression of FAT/CD36 in skeletal muscle (84).  Recent studies have suggested 
that FAT/CD36 is located in mitochondrial and plasma membranes, and co-
immunoprecipitates with CPT-1, with increasing levels of co-immuniprecipitation 
following exercise training (183).  In obesity, there is an increase in plasma FFA, as well 
as in amount of FAT/CD36 located at the plasma membrane, which promotes increased 
uptake of FFA into the muscle (40; 73; 125).  Gender differences in FAT/CD36 
expression in skeletal muscle of obese subjects have been observed, with decreased 
expression of FAT/CD36 in adipose tissue of obese males and increased expression of 
FAT/CD36 in obese females compared to their lean counterparts (53).  While plasma 
FFA and cellular FFA transport are increased, the oxidation of FFA is compromised in 
obesity.  One possible reason for impaired FFA oxidation in spite of increased FFA 
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uptake is that malonyl CoA, an inhibitor of CPT-1, is increased in obesity, thus 
preventing FFA transport into the mitochondria for oxidation (10).  Another explanation 
that has been proposed is that the decreased mitochondrial density in obese subjects 
contributes to decreased oxidative capacity of FFA (105).  Recently it has been suggested 
that decreased contraction-induced translocation of FAT/CD36 to the mitochondrial 
membrane is responsible for the impaired FFA oxidation in obesity (73).  Regardless of 
the explanation, obesity is associated with increased FFA transport across the plasma 
membrane via FAT/CD36 without a subsequent increase in FA oxidation.   
   In order to get a clear picture of fuel metabolism, it is necessary to look at 
storage and oxidation of carbohydrate in addition to fat utilization.  Glycogen 
phosphorylase (GP) is an enzyme which breaks glycogen, the storage form of 
carbohydrate, releasing glucose-1-phosphate.  Once free, glucose-1-phosphate is 
converted to glucose-6-phosphate by phosphoglucomutase in order to be utilized for 
glycolysis (89).  Thus, the GP contributes to carbohydrate utilization by catalyzing the 
breakdown of glycogen for glycolysis.  Numerous variables can impact GP activity.  
Gender differences have been observed in GP expression in response to physical activity 
in that voluntary wheel running decreased GP activity in female, but not male mice (88).   
In addition, skeletal muscle from obese subjects exhibits increased GP activity (4), thus 
suggesting that obese individuals are more likely to use carbohydrate as a substrate.      
 Citrate Synthase (CS) is a critical enzyme in the Kreb’s Cycle, which catalyzes 
the formation of citrate from Acetyl-CoA and oxaloacetate.  While GP is indicative of 
carbohydrate utilization via glycolysis, CS is an indicator of mitochondrial function.  CS 
expression and activity is increased with exercise training (86).  Gender differences in CS 
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mRNA expression in skeletal muscle have been observed, with increased levels in 
females as compared to males, however, no differences in CS activity were observed at 
rest (171).  Further, in the same study, 90 minutes of exercise resulted in increased 
activity of CS in both trained and untrained females, but no change was observed in 
males in either group (171).  Whereas acute exercise increased CS activity in females 
only, exercise training increased CS activity in males and females to an equal degree 
(171).  As one would predict, activity of CS is decreased in obese subjects, and to an even 
greater degree in obese subjects with non-insulin-dependent diabetes mellitus (105; 189).  
Thus, obese subjects demonstrate an impaired capacity for oxidation via the Kreb’s cycle.   
Acute Cellular Regulation of Fat Oxidation: 
AMP-activated protein kinase (AMPK) has been shown to regulate energy 
balance and homeostasis.   Increased AMPK activity is thought to contribute to increases 
in fat oxidation, glucose uptake, glycolysis, and mitochondrial biogenesis when activated 
by muscle contraction (75).  Malonyl CoA is an intermediate in the formation of FFA’s, 
as well as an inhibitor of CPT-1 which controls FA entry into the mitochondria for 
oxidation (135).  Acetyl CoA carboxylase (ACC) regulates synthesis of malonyl CoA, 
thus enhanced activation of ACC results in decreased fat oxidation.  When 
phosphorylated, AMPK can phosphorylate ACC, inhibiting ACC activity and reducing 
the formation of malonyl CoA (165).  This inhibition of malonyl CoA synthesis inhibits 
lipogenesis and promotes lipid oxidation, thus AMPK activity plays a role in lipid 
utilization.  This suggests AMPK is a major contributor to the regulation of fat oxidation 
during exercise.  
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Cellular Regulation of Lipolysis: 
Hormone Sensitive Lipase (HSL) is responsible for catalyzing the hydrolysis of 
triacylglycerol and functions as the rate limiting step in lipid utilization (85).  HSL is 
present in many tissues, but is expressed at high levels in adipose tissue (45).  In order for 
lipid to be utilized as an energy source, it must be broken down from the storage form of 
triacylglycerol to diacylglycerol and then ultimately into individual FFA’s.  Once 
triacylglycerol is hydrolyzed into individual FFA’s, which are transported in the blood 
and taken up by the muscle, these FFA’s may be oxidized in the mitochondria.  
Regulation of HSL activity occurs primarily via phosphorylation, however, translocation 
and composition of the lipid droplet to be hydrolyzed also impact HSL activity (85).  In 
humans, HSL can be activated via phosphorylation at Ser552, Ser649, and Ser650, and 
Ser554.  In rats and mice, Ser554 corresponds to Ser 565, and Ser563 is orthologous to 
human site Ser 552 (45).  In the presence of β-adrenergic stimulation, the Ser563, Ser659, 
and Ser 660 sites are phosphorylated by Protein Kinase A (PKA) via the cyclic AMP 
pathway. The Ser565 site is phosphorylated by AMPK and calcium calmodulin- 
dependent kinase II (CaMKII), while the Ser600 site is a target of the mitogen-activated 
protein kinase via extracellular signal-related kinase (ERK).  Studies have suggested that 
phosphorylation of HSL at Ser 565 inhibits lipolysis, while phosphorylation at Ser 563 
results in increased HSL activity (45).  When the Ser565 site is phosphorylated, it may 
prevent phosphorylation of the regulatory Ser565 site, inhibiting HSL activity (45; 85).  
However, studies on the potential inhibitory effects of AMPK on HSL have produced 
mixed results.  In a study by Watt et al., subjects completed 60 minutes of cycling at 70% 
of VO2max under both normal and low glycogen conditions.  At rest, HSL activity and 
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α2-AMPK phosphorylation were the same under normal and low glycogen conditions.  
When glycogen content was low, α2-AMPK increased to a greater extent during exercise 
than under normal conditions.  Further, HSL activity was lower following exercise under 
low glycogen conditions.  In spite of decreased HSL activity, IMTG was decreased by 
exercise in the low glycogen group.  In L6 myotubes, addition of aminoimidazole-4-
carboxamide (AICAR), an activator of AMPK, resulted in attenuation of HSL activity in 
the presence of epinephrine.  Based on these results, Watt et al. concluded that AMPK 
phosphorylation of HSL inhibits HSL activity and that a mechanism other than HSL may 
contribute to the utilization of IMTG during exercise (213).  In contrast, a similar study 
conducted by Roepstorff et al. concluded that the increased AMPK phosphorylation 
following exercise in a glycogen-reduced state did not impact HSL activity (174).  
However, Roepstorff et al. suggest that increases in other factors, such as ERK 
phosphorylation of HSL, may have negated inhibitory effects of AMPK phosphorylation 
of HSL.   
 In addition to regulation by PKA and cAMP mechanisms, HSL activity may be 
altered by ERK1/2.  When ERK1/2 is activated via phosphorylation at the Thr 202/Tyr 
204 residues, ERK1/2 phosphorylates HSL at the Ser600 residue.  Phosphorylation of 
HSL at the Ser600 residue by ERK1/2 enhances HSL activity and subsequently enhances 
lipolysis.  By inhibiting activation of ERK1/2 in 3T3-L1 adipose cells, Greenberg et al. 
found a 30% decrease in catecholamine-stimulated lipolysis.  Further, by activating 
ERK1/2, a 2-fold increase in glycerol release was observed in 3T3-L1 cells (69).  Figure 
14 below illustrates the regulation of HSL activity via phosphorylation by various 
substrates.    
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Figure 15. Cellular regulation of HSL in adipose tissue (85).  
Thus, exercise uses a dynamic interaction between lipolysis and fat oxidation in 
the muscle to effectively use fat as a substrate.  The regular use of fat by the muscle is 
critical in maintaining a favorable body composition.  Thus, it is critical to understand the 
mechanisms that regulate both lipolysis and fat oxidation.   
Obesity vs. Exercise Training: 
 Alteration in oxidative gene expression, such as CPT-1, FAT/CD36, GP, and CS, 
may contribute to metabolic changes observed in obese and endurance-trained subjects.  
Both obesity and endurance training result in increases in uptake of FFAs and IMTG 
accumulation.  This is known as the “athlete’s paradox,” as endurance trained athletes 
exhibit an increase in IMTG accumulation similar to the IMTG accumulation observed in 
obese individuals (65).  In the obese, this increase in IMTG contributes to insulin 
resistance (104).  However, endurance-trained individuals with increased IMTG show 
increased insulin sensitivity (65).  This difference in insulin utilization accompanying 
IMTG accumulation in trained and obese individuals is believed to be due to differences 
in lipid oxidation rates.   Trained individuals are able to oxidize more of the accumulated 
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IMTG, thus increasing insulin sensitivity (65).  Various theories have been proposed to 
explain the link between IMTG accumulation and insulin resistance in sedentary and 
obese populations.  One explanation is that metabolites of IMTG, such as diacylglycerol 
(DAG) or ceremide, activate a serine kinase cascade, which in turn decreases activity of 
the insulin receptor substrate-1 (IRS-1) associated phosphatidylinositol 3-kinase (70; 97; 
161).  Decreased activity of IRS-1 results in impaired glucose transport, thus it 
contributes to insulin resistance (111).  Another theory suggests that the activation of 
inflammatory pathways (NFκB and JNK) during lipid uptake/fat accumulation promote 
phosphorylation of IRS-1 and thus impair insulin signaling (97; 212).  
 Peripheral insulin sensitivity is positively affected by exercise.  Improvements in 
blood glucose regulation occur after an acute exercise bout, as well as long-term with 
regular exercise training (38; 39).  Acute exercise promotes increased translocation of 
GLUT4 to the cell membrane for glucose uptake by activating AMPK (121), while 
exercise training can improve the muscles’ ability to respond to insulin by increasing the 
sensitivity of the insulin receptor thus enhancing glucose uptake (181).  The increased 
insulin sensitivity and blood glucose handling result in a decreased risk for development 
of Type II diabetes.  With weight loss, there are additive changes in insulin sensitivity 
due to exercise (66).  However, changes in insulin sensitivity still occur with exercise in 
the absence of changes in body composition (15).  Through alteration of insulin 
sensitivity and blood glucose regulation, exercise decreases the risk of developing Type 
II diabetes and being diagnosed with the metabolic syndrome.  
Due to the physiologic adaptations invoked with endurance training, trained 
individuals benefit from enhanced fat oxidation which results in the sparing of 
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carbohydrate.  During an exercise bout of low-moderate relative intensity, trained 
individuals exhibit a decreased uptake in plasma glucose and a sparing of glycogen 
through slowed glycogenolysis (9; 37; 54; 78; 79; 95).  On the other hand, obese 
individuals do not have enhanced fat oxidation in spite of increased fat uptake into 
muscle cells (209).  Thus, obese individuals will store more fat due to an impaired ability 
to oxidize the fat.   
Estrogens and Fuel Metabolism: 
 In addition to obesity, conditions where ovarian hormone levels are altered, such 
as menopause, contribute to alteration in fuel utilization.  Whereas it is well established 
that glycogen content, diet, training status, and intensity level all influence fuel utilization 
during exercise, the role of gender and thus gender-specific hormones is still under 
investigation.  Results of several studies have shown that females possess greater levels 
of fat oxidation during exercise at the same relative intensity as males (178; 198-200). 
In females, the cross-over point occurs at a higher relative exercise intensity 
compared to males, thus females exhibit a greater amount of fat oxidation at all relative 
intensity levels (208).  These findings would suggest a potential role of the sex hormones, 
the estrogens in particular, in fat oxidation.  Changes following ovarian hormone loss 
provide further support for a role of sex hormones in fuel metabolism.  Many animal 
studies have been conducted using ovariectomy as the model of menopause.  Hansen et 
al. found that in ovariectomized female rats estradiol supplementation resulted in 
decreased synthesis of FFA’s, whereas progesterone supplementation elevated FFA 
synthesis compared to estradiol supplementation.  This would suggest that estradiol may 
promote FFA oxidation over FFA storage (74).   
 -  - 56
 
Ovarian Hormones May Promote Fat Oxidation: 
It would be logical to hypothesize that greater fat oxidation by females during 
exercise might be indicative of gender differences in AMPK activation as well.  Most 
recently, Roepstorff et al. demonstrated that women oxidize significantly more fat than 
men during submaximal exercise independent of AMPK activation (173).  Specifically, 
phosphorylation of αAMPK (Thr172), as well as activity of α2AMPK, were equal in 
males and females at rest, but elevated only in males following a bout of exercise.  These 
findings suggest that AMPK is not the mechanism responsible for gender differences in 
fat oxidation, leaving the area open to further exploration (173).  From an anatomical 
standpoint, Roepstorff et al. suggest that gender differences in fat oxidation are due to 
sex-specific muscle morphology based on a positive correlation between fat oxidation 
and type I fibers, as well as capillary density (173).  However, D’Eon et al. recently 
demonstrated that estradiol and 2-hydroxyestradiol (2-HE2), an estrogen metabolite, can 
increase AMPK phosphorylation in C2C12 myotubes (43).  With low doses of estradiol, 
AMPK phosphorylation was observed to increase ~1.6 fold, while in high doses, AMPK 
phosphorylation increased ~3.0 fold.  At all concentrations tested, 2-HE2 resulted in 
increased AMPK phosphorylation in C2C12 myotubes (43).  These results suggest that 
estradiol and estradiol metabolites may contribute to gender differences in AMPK 
activation.  
 Using OVX mice, I have found decreased AMPK phosphorylation in the tibialis 
anterior (TA) muscle compared to their SHAM counterparts at rest.  However, when 
fatigue was induced using in situ contractions, AMPK phosphorylation increased from 
baseline in the OVX group, whereas the SHAM group showed no further increases in 
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phosphorylation.  In contrast, when the muscle was placed in an in vitro bath, 
phosphorylation of AMPK was almost undetectable in both the SHAM and OVX groups 
at rest and increased to the same degree in both groups following contraction.  These data 
suggest that a circulating factor present in the blood of female animals with ovaries intact 
contributes to AMPK phosphorylation at rest.  However, removal of the ovaries results in 
decreased AMPK phosphorylation at rest and increased AMPK phosphorylation in 
response to contraction stimulus (Wohlers et al. 2008-in review).  These results 
demonstrate that ovarian function impacts AMPK phosphorylation at rest and following 
contraction in skeletal muscle, thus potentially altering fuel utilization.  This is in line 
with the results of Roepstorff et al. in which females had elevated AMPK 
phosphorylation at rest and did not increase AMPK phosphorylation with exercise, while 
males exhibited significantly increased AMPK phosphorylation with exercise (173).  
Taken together, theses studies demonstrate that the ovarian hormones may induce 
changes in AMPK phosphorylation in human and mouse skeletal muscle.   
Phosphorylation of ERK1/2 is also altered by ovarian hormone status. 
Specifically, I found ERK2 phosphorylation to increase in both SHAM and OVX mice in 
response to in situ contraction of the TA muscle.  However in the OVX group, the 
increase in phosphorylation is significantly greater than in the SHAM group (Wohlers et 
al. 2008-in review).  Thus, in skeletal muscle, ovarian hormones appear to inhibit the 
ability of muscle to increase ERK1/2 phosphorylation with contraction.  
Ovarian Hormones May Affect Lipolysis: 
 Based on the observed differences in fat mass between pre-and post-menopausal 
females, it may be hypothesized that ovarian hormone status may result in differences in 
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lipolysis and/or lipogenesis.  Roepstorff et al. addressed this hypothesis in a study of 
males and females and found that HSL mRNA expression and protein content was higher 
in females than males (195).  However, total HSL activity was not different between the 
sexes.  Males exhibited increased phosphorylation of Ser659, and HSL activity 
normalized to HSL protein content, as compared to females.  Roepstorff et al. suggested 
that increased oxidation of fat in females versus males is due to the greater IMTG content 
in the muscle, rather than enhanced lipolysis in the adipose tissue of females versus males 
(195).  There are few studies examining regulation of lipolysis specifically in females 
versus males.   
In cats, at 24 weeks following ovariohysterectomy, fat mass increased to a greater 
degree than lean mass, resulting in a significant shift in body composition.  Cats were less 
physically active following surgery, with a 52% decrease in activity by week 24.  Serum 
glucose and triglyceride concentrations, as well as circulating leptin levels, were 
significantly increased at week 24 as compared to all other time points.  LPL, HSL, and 
adiponectin mRNA expression in adipose tissue was decreased, and IL-6 expression was 
increase at 24 weeks as compared to baseline.  The decreases in HSL and LPL would 
suggest alterations in lipolysis and uptake occur following loss of ovarian hormones, 
while the decrease in adiponectin would suggest ovarian hormone loss might reduce 
insulin sensitivity.  Thus, ovariohysterectomy resulted in anthropomorphic changes, as 
well as alteration in expression of genes which impact fuel utilization (16).      
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While the benefits of exercise have been widely demonstrated in males and pre-
menopausal females, little is known about the benefits of exercise as a preventative 
measure for the health problems that many women face when they reach 
menopause.  Until recently, HRT was the most common treatment to smooth the 
transition into menopause and prevent the onset of post-menopausal conditions such 
as osteoporosis and metabolic syndrome.  
 
Women entering menopause are susceptible to changes in fat metabolism that place them 
at increased risk for the metabolic syndrome: 
 
 Following the onset of menopause, physiological changes occur which increase 
the risk of developing the metabolic syndrome.  Unfortunately, at this point preventative 
treatment for women remains unclear.  However, one would predict that increased 
physical activity would be effective.  Metabolic syndrome prevalence is lower in 
adolescent males and females who are moderately physically active than in those with 
low levels of activity (148).  Exercise has been utilized as an effective treatment of the 
metabolic syndrome in pre-menopausal women, mostly through exercise effects on 
insulin sensitivity and weight loss.  Multiple studies have suggested that physical activity 
in women decreases risk of CVD and is an effective treatment in those who already have 
CVD, however, these studies focus on pre-menopausal women (See review Oguma 2004) 
(147).   
HRT: 
Definition: 
Hormone replacement therapy (HRT) is a means to increase or replace female 
hormones during and following menopause.  HRT typically consists of estrogen 
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supplementation alone, or estrogen in conjunction with progesterone.  Prior to the 
Women’s Health Initiative, HRT was widely prescribed in order to prevent the negative 
side effects associated with menopause, including the metabolic syndrome, 
cardiovascular disease, and osteoporosis.  
Health benefits of HRT: 
As described above, menopause results in increased risk of development of the 
metabolic syndrome, CVD, and osteoporosis.  Use of HRT has been shown to decrease 
the risk for and/or improve symptoms of, these conditions.  HRT has positive effects on 
bone health and remodeling.  HRT can attenuate the onset of the metabolic syndrome by 
decreasing abdominal fat by approximately 6.8% (180).  Also, some studies suggest HRT 
use leads to improvements in insulin sensitivity (143; 190).  However, results on the 
effects of HRT on insulin sensitivity are mixed, as the type of HRT, method of use, and 
study population produced different results (6).  HRT leads to improvements in blood 
lipid profile, resulting in increased HDL cholesterol and decreased LDL cholesterol 
(141).  By impacting body composition, insulin sensitivity, and blood lipid profile, HRT 
decreases the risk of developing the metabolic syndrome in post-menopausal women.   
Negative side effects of HRT: 
Based on the positive effects of HRT and osteoporosis, it would appear that use of 
HRT in post-menopausal women is favorable.  However, negative side-effects reportedly 
linked to HRT use have led many to question its use.  These side effects include 
increased risk for stroke, blood clots, and heart disease (145).  Further, some studies show 
increased occurrence of various cancers among women taking HRT as compared to post-
menopausal women not on HRT (145).  These findings have been summarized in the 
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Women’s Health Initiative, which began in 1991, and have resulted in a significant 
decline in prescription of HRT to post-menopausal women.  
Is Exercise Training a Useful  Alternative to HRT in Post-menopausal Women?: 
  It is clear that menopause results in many changes that negatively impact the 
health of females.  With the recommendation to reduce HRT use following the release of 
the Women’s Health Initiative, another mechanism of treatment should be sought out.  
Exercise has been utilized as an effective treatment of the metabolic syndrome in males 
and pre-menopausal females, mostly through exercise effects on weight loss and insulin 
sensitivity.  Multiple studies have suggested that physical activity in women decreases 
risk of CVD and is an effective treatment in those who already have CVD.  However, 
these studies focus on pre-menopausal women (See review Oguma 2004) (147).  Based 
on the knowledge of the beneficial effects of exercise, and its successful use in other 
populations as preventative medicine, study of exercise effects in prevention of the 
metabolic syndrome in post-menopausal women is warranted.   
 In summary, exercise is beneficial for cardiovascular health, as well as for 
preventing the onset of the metabolic syndrome.  Further, exercise training results in 
positive metabolic changes, such as an increased ability to oxidize fat, thus sparing 
glycogen stores.  Post-menopausal women experience alterations in metabolism that 
increase risk of developing the metabolic syndrome and CVD.  In light of the WHI, and 
based on knowledge of therapeutic and preventative uses of exercise, the possibility of 
exercise prescription in place of HRT in prevention of the metabolic syndrome in post-
menopausal women should be pursued.     
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APPENDIX A: Limitations 
 This study involves the analysis of mice ovariectomized at 8 weeks of age in 
attempting to understand mechanisms involved with menopause, which occurs much later 
in the lifespan, at approximately 17-25 months.  Therefore, it is possible that factors not 
present in young mice may be involved in the onset of metabolic syndrome in post-
menopausal females.  However, since the occurrence of metabolic syndrome increases 
with age independent of estrogen status, it is important to understand the impact of aging 
and estrogen status as individual phenomenon.  Thus, we believe that the model selected 
is most appropriate, as it is the only way to look at the effects of estrogen independent 
from changes that occur with age.  Furthermore, as this study was performed in mice, 
findings would need to be confirmed in humans before they could be applied to treatment 
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